PRN: Next-Generation Cancer Diagnostics Market Forecast 2017-2027

16/mag/2017 16:01:52 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Next-Generation Cancer Diagnostics Market Forecast 2017-2027

 
[16-May-2017]
 

LONDON, May 16, 2017 /PRNewswire/ --

Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques

The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021, says Visiongain.

While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.

Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 166-page report you will receive 87 charts - all unavailable elsewhere.

The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.

• 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
- Advanced PCR Techniques
- In Situ Hybridization (ISH)
- Circulating Tumour Cells (CTCs) Analysis
- Microarray
- Next-Generation Sequencing (NGS)

• Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
- US
- EU5
- Japan
- China
- India
- Brazil
- Russia
- Rest of the World

• Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
- Roche Diagnostics
- Abbott Laboratories
- Qiagen
- Thermo Fisher Scientific
- Agilent Technologies
- Hologic
- Illumina
- Myriad Genetics

• SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on: https://www.visiongain.com/Report/1867/Next-Generation-Cancer-Diagnostics-Market-Forecast-2017-2027

The companies mentioned are:

454 Life Sciences
Abbott Laboratories
AbbVie
AbVitro
Advanced Cell Diagnostics
Advanced Liquid Logic
Affymetrix
Agendia
Agilent Technologies
Ambry
Amgen
Annoroad
Applied Biosystems
ARCH Venture Partners
AstraZeneca
Atossa Genetics
AvanSci
Aviva Biosciences
BD
Berry Genomics
BGI
Bina Technologies
Biobase
Biochain
BioFluidica
BioMarin Pharmaceutical
bioMérieux
Bio-Rad
BioServe India
BlueGnome
Bristol-Myers Squibb
Bruker
Cancer Genetics
Cepheid
CLC bio
CompanionDx
Counsyl
Crescendo Bioscience
CytoTrack
Dako
DakoCytomation
Danaher
DiagnoCure
DxS
Eli Lilly
Enzymatics
Epic Sciences
Epicentre Technologies
Epigenomics
Exact Sciences
Fidelity Management
Fluidigm
Fluxion
GeneDx
Genentech
Genia Technologies
Genomic Health
Gen-Probe
GnuBio
HalioDX
Hitachi High-Technologies
Hologic
Idaho Technology
IGEN International
Illumina
Ingenuity Systems
Insilico Medicine
Invitae
Invitrogen
Ipsogen
Iquum
Iris Molecular Diagnostics
Janssen Biotech
Janssen Diagnostics
LabCorp
Life Technologies
Luminex Corporation
Manostring Technologies
Merck
Miltenyi Biotec
Mylan
Myraqa
Myriad Genetics
NextBio
Oncolys BioPharma
Ono Pharmaceutical
Oxford Nanopore
Pacific Biosciences
Pathway Genomics
Pathway Pharmaceuticals
Pensabio
PerkinElmer
Pfizer
Prosigna
Qiagen
Qiagen Marseille
Quest Diagnostics
Quidel
RainDance Technologies
Rarecells
Roche Diagnostics
Sakura
Sanofi
ScreenCell
Siemens
Signature Diagnostics
Silicon Biosystems
SRI Biosciences
Stratos Genomics
Sysmex
Takeda
Thermo Fisher Scientific
Twist Bioscience
Ventana Medical Systems
Verinata Health
Vysis

List of Organizations Mentioned in the Report
Actionable Genome Consortium
Arizona State University
Carnegie Mellon University
First Oncology Research and Advisory Center
Genomics England
Institut Curie
MGH Cancer Center
Massachusetts Institute of Technology
National Cancer Center
Paris-Descartes University
Pennsylvania State University

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl